Zoster Vaccine Recombinant, Adjuvanted
Herpes Zoster
GlaxoSmithKlinevaccinePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Herpes Zoster cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capsaicin NeurogesX | Phase 3 | BBB |
Zoster Vaccine, Live, (Oka/Merck) Louis Stokes VA Medical Center | Phase 4 | BBB |
Pregabalin CMH Kharian Medical College | Phase 4 | BB |
Gabapentine Dominik Irnich | Phase 4 | BB |
Gerpevir Cttq | Phase 4 | BB |
View all 26 →
Same molecule, other indications
Zoster Vaccine Recombinant, Adjuvanted is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →